Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2004;35:2837-2842
Published online before print November 4, 2004, doi: 10.1161/01.STR.0000148237.13659.e6
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
35/12/2837    most recent
01.STR.0000148237.13659.e6v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nanba, R.
Right arrow Articles by Iwasaki, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nanba, R.
Right arrow Articles by Iwasaki, Y.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Substance via MeSH
Related Collections
Right arrow Angiogenesis
Right arrow Other diagnostic testing
Right arrow Oxidant stress

(Stroke. 2004;35:2837.)
© 2004 American Heart Association, Inc.


Original Contributions

Increased Expression of Hepatocyte Growth Factor in Cerebrospinal Fluid and Intracranial Artery in Moyamoya Disease

Rina Nanba, MD, PhD; Satoshi Kuroda, MD, PhD; Tatsuya Ishikawa, MD, PhD; Kiyohiro Houkin, MD, PhD Yoshinobu Iwasaki, MD, PhD

From the Department of Neurosurgery (R.N., S.K., T.I., K.H., Y.I.), Hokkaido University Graduate School of Medicine, Japan.

Correspondence to Dr Satoshi Kuroda, Department of Neurosurgery, Hokkaido University Graduate School of Medicine, North 15 West 7, Kita-Ku, Sapporo 060-8638 Japan. E-mail skuroda{at}med.hokudai.ac.jp

Background and Purpose— The etiology of moyamoya disease still remains unknown. This study was aimed to explore the role of hepatocyte growth factor (HGF), a strong inducer of angiogenesis, in development of moyamoya disease.

Methods— We studied cerebrospinal fluid (CSF) from 39 patients with moyamoya disease (24 children and 15 adults), 6 control patients with cervical spondylosis, and 7 control patients with internal carotid artery occlusion. CSF level of HGF was determined by enzyme-linked immunosorbent assay technique. We also evaluated the distribution of HGF and its cellular receptor c-Met in the carotid fork obtained from 2 patients with moyamoya disease and 2 control patients.

Results— CSF level of HGF was 408.2±201.6 pg/mL and 443.2±193.5 pg/mL in patients with cervical spondylosis and internal carotid artery occlusion, respectively (mean±SD). On the other hand, CSF level of HGF was 820.3±319.0 pg/mL in patients with moyamoya disease, being significantly higher than those in 2 control groups (P<0.01). Both HGF and c-Met were widely distributed in the media and thickened intima of the carotid fork in patients with moyamoya disease but not in control patients.

Conclusions— This study revealed that HGF is densely found in the carotid fork, and its CSF level is markedly elevated in moyamoya disease, suggesting that HGF may be a key protein for pathogenesis of moyamoya disease.


Key Words: angiogenesis • hepatocyte growth factor • moyamoya disease • protooncogene protein c-met




This article has been cited by other articles:


Home page
NEJMHome page
R. M. Scott and E. R. Smith
Moyamoya Disease and Moyamoya Syndrome
N. Engl. J. Med., March 19, 2009; 360(12): 1226 - 1237.
[Full Text] [PDF]


Home page
StrokeHome page
S. Kuroda, N. Hashimoto, T. Yoshimoto, Y. Iwasaki, and for the Research Committee on Moyamoya Disease in
Radiological Findings, Clinical Course, and Outcome in Asymptomatic Moyamoya Disease: Results of Multicenter Survey in Japan
Stroke, May 1, 2007; 38(5): 1430 - 1435.
[Abstract] [Full Text] [PDF]